Pacira BioSciences, Inc. (PCRX) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $22.87, but acceptable to hold if already in. Reason: Market cap $0.90B below $1B minimum.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable... Read more
Hold if already holding. Not a fresh buy at $22.87, but acceptable to hold if already in. Reason: Market cap $0.90B below $1B minimum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Market cap $0.90B below $1B minimum. Not in investable universe. Score 4.8/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Pacira BioSciences, Inc.
Latest news
- NEWS PCRX (Pacira BioSciences Inc.) reports steep Q4 2025 EPS miss while shares rise 3.6 percent on favorable investor sentim — Cổng thông tin điện tử tỉnh Tây Ninh negative
- NEWS Pacira Biosciences Inc Live Share Prices and Trades. PCRX.US Live Streaming Share Prices. - London South East — London South East neutral
- NEWS Pacira Biosciences Live Share Prices and Trades. PCRX.US Live Streaming Share Prices. - London South East — London South East neutral
- NEWS Do options traders know something about Pacira BioSciences stock we don't? - MSN — MSN neutral
- NEWS Is It Too Late to Buy Pacira BioSciences Inc (PCRX) After 4.3% R - GuruFocus — GuruFocus neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $22.87, but acceptable to hold if already in. Reason: Market cap $0.90B below $1B minimum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Market cap $0.90B below $1B minimum. Not in investable universe. Target $25.48 (+11.4%), stop $21.26 (−7.6%), A.R:R 1.4:1. Score 4.8/10, moderate confidence.
Take-profit target: $25.48 (+11.5% upside). Target $25.48 (+11.4%), stop $21.26 (−7.6%), A.R:R 1.4:1. Stop-loss: $21.26.
Market cap $0.90B below $1B minimum.
Pacira BioSciences, Inc. trades at a P/E of 175.0 (forward 6.2). TrendMatrix value score: 7.3/10. Verdict: Hold.
13 analysts cover PCRX with a consensus score of 3.8/5. Average price target: $29.
What does Pacira BioSciences, Inc. do?Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain...
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.